Arcus Biosciences Announces Participation at Leerink Partners Roundtable Series: Rare Disease & Oncology
September 20 2018 - 4:05PM
Business Wire
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage
biopharmaceutical company focused on creating innovative cancer
immunotherapies, today announced Terry Rosen, Ph.D., Chief
Executive Officer, and Jennifer Jarrett, Chief Operating Officer
and Chief Financial Officer, will participate in a fireside chat at
the Leerink Partners Roundtable Series: Rare Disease & Oncology
on Wednesday, October 3, 2018, at 10:30 am ET at the Lotte New York
Palace, in New York.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage biopharmaceutical company
focused on creating innovative cancer immunotherapies. Arcus
has several programs targeting important immuno-oncology pathways,
including a dual adenosine receptor antagonist AB928, which is in a
Phase 1/1b program to evaluate AB928 in combination with other
agents in multiple tumor types, and an anti-PD-1 antibody AB122,
which is being evaluated in a Phase 1 trial and is being tested in
combination with Arcus’s other product candidates. Arcus’s other
programs include AB154, an anti-TIGIT antibody, which is in a Phase
1 trial to evaluate AB154 as monotherapy and in combination with
AB122, and AB680, a small molecule inhibitor of CD73, which is in
IND-enabling studies. Arcus has extensive in-house expertise
in medicinal chemistry, immunology, biochemistry, pharmacology and
structural biology. For more information about Arcus Biosciences,
please visit www.arcusbio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180920005454/en/
Arcus BiosciencesJennifer Jarrett,
510-694-6261jjarrett@arcusbio.comorNicole Arndt,
510-284-4728narndt@arcusbio.com
Arcus Biosciences (NYSE:RCUS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arcus Biosciences (NYSE:RCUS)
Historical Stock Chart
From Apr 2023 to Apr 2024